Prospective trials with lower toxicity outpatient treatment regimens are needed to obtain more responses in elderly patients with Amyloid Light-chain amyloidosis.

Study of the UK National Amyloidosis Centre (2005-2012)

- 295 patients with systemic Amyloid Light-chain amyloidosis
- 75 years or older (median age 78.5 years)

Treatment

- Patients achieving very good partial response or better
  - Median overall survival: 6.2 years

- Non-responders
  - Median overall survival: 1.5 years

Independent poor prognostic factors:

- Cardiac involvement
- Systolic blood pressure <100mmHg
- Performance status ≥2
- Achieving less than very good partial response (at 6 months landmark analysis)

Sachchithanantham et al., Haematologica, 2015